Schonewolf Caitlin A, Jolly Shruti, Dess Robert T
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.
Semin Radiat Oncol. 2021 Apr;31(2):112-119. doi: 10.1016/j.semradonc.2020.11.005.
Radiation therapy plays an integral role in the treatment of all stages of non-small cell lung cancer. Survival outcomes are improving, but radiation therapy remains associated with long-term toxicity. Recently, it has become evident that the heart is an important organ at risk for treatment-related morbidity. In this review, we discuss the hypothesis that particle radiation therapy offers superior dosimetry compared with photon-based treatment, and that this comparative advantage translates into clinically meaningful cardiac toxicity reduction with similar local tumor control. We discuss the evidence in non-small cell lung cancer to date, the ongoing prospective trials that may provide additional insight, and the opportunities to optimally integrate particle therapy into future prospective investigation.
放射治疗在非小细胞肺癌各阶段的治疗中发挥着不可或缺的作用。生存结局正在改善,但放射治疗仍与长期毒性相关。最近,有一点已变得很明显,即心脏是一个易受治疗相关发病率影响的重要器官。在本综述中,我们讨论这样一种假说:与基于光子的治疗相比,粒子放射治疗具有更优的剂量测定,并且这种比较优势转化为在局部肿瘤控制相似的情况下临床上有意义的心脏毒性降低。我们讨论了迄今为止非小细胞肺癌方面的证据、可能提供更多见解的正在进行的前瞻性试验,以及将粒子治疗最佳地整合到未来前瞻性研究中的机会。